Within 10 years of surgery, men younger than 60 years are more likely to die from prostate cancer than from other causes.
Only 6.7% of men reported erections that were as good after radical prostatectomy, as before—much lower than would be expected by IIEF-5 scores.
Even patients who quit smoking less than 10 years after radical prostatectomy are at increased risk.
Studies suggest that these cholesterol-lowering drugs can improve treatment of genitourinary cancers and prevent contrast-induced nephropathy.
Low serum testosterone levels within the first year of androgen-deprivation therapy (ADT) is associated with improved cause-specific survival.
The researchers found that 12% of the participants experienced treatment decisional regret.
Highest risk during first 6 months of ADT among men who had cardiovascular events before treatment.
Also, no significant associations found between vitamin D-related SNPs and fatal prostate cancer
In a study, not a single case of metastatic disease developed among 449 men who had a tumor grade of Gleason 6 or less at radical prostatectomy.
Doctors should ask women about the medical history of their first-degree male relatives, researchers say
African American patients are less likely than Caucasians to receive intensity-modulated radiation therapy for localized prostate cancer.
Meta-analysis shows that use of medication is associated with an 18% lower risk.
Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.
The average time to return of continence and potency following prostatectomy was significantly shorter in the allograft than no-allograft group.
Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.
Adding bicalutamide improves overall survival among patients with advanced nonmetastatic hormone-naïve prostate cancer.
Cancer-specific and overall survival is decreased in men with intermediate-risk versus low-risk tumors.
Researchers observed a significant 36% decreased overall and prostate cancer-specific mortality.
The 4Kscore enables better identification of men who harbor high-grade prostate cancer.
The 5-year risk of overall mortality is decreased by 50% compared with androgen deprivation therapy alone.
This medication sequence was associated with longer progression-free and overall survival compared with the reverse.
Researchers found elevated familial risks for testicular, prostate, bladder, and kidney cancers.
Prostate cancer progression was delayed by a median 10 months in statin users.
A history of testicular cancer was associated with a greater likelihood of prostate cancer overall and intermediate- or high-risk disease.
No higher risk of adverse pathology among men on active surveillance who delayed surgery until signs of disease progression.
The proportion of men diagnosed with intermediate- or high-risk disease rose 6% from 2011 to 2013, study finds.
Risk factors include male gender, distant disease, increasing age, race/ethnicity
Research raises concerns about possible overuse of radiation therapy
Sexual function declines for both men and women following radical prostatectomy, but some aspects of care may help couples.
From 2004 to 2009, there was a marked increase in observation (watchful waiting and active surveillance) among men with low-risk prostate cancer.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)